Skip to main content

Table 1 Patient and tumor characteristics

From: The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer

 

Surgery only

Adjuvant CT

p value

N = 187

N = 430

Sex

  

0.911

 M

127 (67.9)

294 (68.4)

 

 F

60 (32.1)

136 (31.6)

 

Age (median, years)

  

0.015

 

70 (31~96)

66 (29~90)

 

 <65

58 (31.0)

193 (45.0)

0.001

 ≥65

129 (69.0)

236 (55.0)

 

Performance status (ECOG)

  

0.387

 0

181 (96.8)

422 (98.1)

 

 1

4 (2.1)

6 (1.4)

 

 2

1 (0.5)

2 (0.5)

 

 3

1 (0.5)

0

 

Preoperative CEA (ng/mL)

2.2 (0.2~98.8)

2.4 (0.2~169.1)

0.710

Scope of LN dissection

  

0.004

 D1

23 (12.5)

31 (7.2)

 

 D1 + A

1 (0.5)

23 (5.4)

 

 D1 + B

5 (2.7)

23 (5.4)

 

 D2

151 (82.1)

347 (81.1)

 

 D3

4 (2.2)

4 (0.9)

 

Histology

  

0.209

 Differentiated

88 (47.1)

226 (52.6)

 

 Undifferentiated

99 (52.9)

204 (47.4)

 

Lymphatic invasion

  

0.948

 No

60 (32.1)

136 (31.6)

 

 Yes

127 (67.9)

293 (68.1)

 

 Unknown

0

1 (0.2)

 

Depth of tumor invasion (AJCC 7th)

   

T stage

  

0.073

 T1a

3 (1.6)

3 (0.7)

 

 T2

26 (13.9)

69 (16.05)

 

 T3

91 (48.7)

165 (38.4)

 

 T4a

58 (31.0)

160 (37.2)

 

 T4b

8 (4.3)

24 (5.6)

 

N stage

  

<0.001

 N0

55 (29.4)

70 (16.28)

 

 N1

48 (25.7)

104 (24.19)

 

 N2

48 (25.7)

108 (25.12)

 

 N3a

25 (13.4)

88 (20.47)

 

 N3b

11 (5.9)

60 (13.95)

 

Stage

  

0.002

 IIA

74 (39.6)

102 (23.72)

 

 IIB

35 (18.7)

89 (20.7)

 

 IIIA

27 (14.4)

67 (15.58)

 

 IIIB

24 (12.8)

92 (21.39)

 

 IIIC

27 (14.4)

78 (18.60)

 
  1. CT chemotherapy